Eli Lilly’s Olomorasib Posts a 62% Response Rate in Lung Cancer Study

Your call?🐂 Bullish🐻 Bearish

62%

lung cancer response rate

The 77-patient combination group had median progression-free survival of 11.6 months. First randomized Phase 3 data are expected in the first half of 2027.